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Genetic determinants of common epilepsies: a meta-analysis 
of genome-wide association studies
International League Against Epilepsy Consortium on Complex Epilepsies*
Summary
Background The epilepsies are a clinically heterogeneous group of neurological disorders. Despite strong evidence for 
heritability, genome-wide association studies have had little success in identiﬁ cation of risk loci associated with 
epilepsy, probably because of relatively small sample sizes and insuﬃ  cient power. We aimed to identify risk loci 
through meta-analyses of genome-wide association studies for all epilepsy and the two largest clinical subtypes 
(genetic generalised epilepsy and focal epilepsy).
Methods We combined genome-wide association data from 12 cohorts of individuals with epilepsy and controls from 
population-based datasets. Controls were ethnically matched with cases. We phenotyped individuals with epilepsy 
into categories of genetic generalised epilepsy, focal epilepsy, or unclassiﬁ ed epilepsy. After standardised ﬁ ltering for 
quality control and imputation to account for diﬀ erent genotyping platforms across sites, investigators at each site 
conducted a linear mixed-model association analysis for each dataset. Combining summary statistics, we conducted 
ﬁ xed-eﬀ ects meta-analyses of all epilepsy, focal epilepsy, and genetic generalised epilepsy. We set the genome-wide 
signiﬁ cance threshold at p<1·66 × 10–⁸.
Findings We included 8696 cases and 26 157 controls in our analysis. Meta-analysis of the all-epilepsy cohort identiﬁ ed 
loci at 2q24.3 (p=8·71 × 10–¹⁰), implicating SCN1A, and at 4p15.1 (p=5·44 × 10–⁹), harbouring PCDH7, which encodes a 
protocadherin molecule not previously implicated in epilepsy. For the cohort of genetic generalised epilepsy, we noted 
a single signal at 2p16.1 (p=9·99 × 10–⁹), implicating VRK2 or FANCL. No single nucleotide polymorphism achieved 
genome-wide signiﬁ cance for focal epilepsy.
Interpretation This meta-analysis describes a new locus not previously implicated in epilepsy and provides further 
evidence about the genetic architecture of these disorders, with the ultimate aim of assisting in disease classiﬁ cation 
and prognosis. The data suggest that speciﬁ c loci can act pleiotropically raising risk for epilepsy broadly, or can have 
eﬀ ects limited to a speciﬁ c epilepsy subtype. Future genetic analyses might beneﬁ t from both lumping (ie, grouping 
of epilepsy types together) or splitting (ie, analysis of speciﬁ c clinical subtypes).
Funding International League Against Epilepsy and multiple governmental and philanthropic agencies.
Copyright © International League Against Epilepsy Consortium on Complex Epilepsies. Open Access article 
distributed under the terms of CC BY.
Introduction
Epilepsy is a common disorder, aﬀ ecting up to 4% of 
people at some time in life.1 The disorder includes a 
group of heterogeneous syndromes deﬁ ned by clinical, 
electroencephalographic (EEG), and brain imaging 
criteria.2 Broadly, the epilepsies are divided clinically into 
generalised and focal forms. Genetic factors contribute 
to both, as shown by ﬁ ndings from familial aggregation 
and twin studies.3 Causative mutations in many genes, 
including some genes coding for ion channel subunits 
and others involved in synaptic function or brain develop-
ment, have been reported.3,4 Most of these ﬁ ndings were 
reported in patients with fairly rare familial epilepsies 
segregating in a Mendelian way or epilepsies arising 
from de-novo mutations (particularly in patients with 
severe infantile epilepsies).5–7 
The genetic determinants underlying the common 
epilepsies, for which clinical genetic data suggest 
complex inheritance, remain largely unknown. Some 
evidence suggests a role for rare sequence and copy 
number variants,8–10 whereas the contribution of 
common polymorphisms is still unclear,11,12 partly as a 
result of the relatively small sample sizes analysed 
to date. 
Findings from the largest genome-wide association 
study (GWAS) in epilepsy so far, including 3445 patients 
with focal epilepsy,13 showed no variants of genome-
wide signiﬁ cance. More recently, ﬁ ndings from a study 
of 1018 patients with mesial temporal lobe epilepsy with 
hippocampal sclerosis (a subtype of focal epilepsy) 
implicated the 2q24.3 region around the gene encoding 
the sodium channel SCN1A,14 and ﬁ ndings from an 
independent study of Han Chinese patients with known 
or suspected lesional focal epilepsy showed evidence for 
a risk allele at 1q32 on the basis of a discovery sample of 
504 cases.15
For generalised epilepsy, a GWAS included 
1527 European patients with genetic generalised 
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epilepsies in the discovery analysis and 1493 patients in 
the replication cohort; investigators reported evidence for 
common risk alleles at 2p16.1 and 17q21.32, and 
suggestive evidence at the SCN1A locus.16 Additionally, 
associations were reported for the juvenile myoclonic 
subtype of genetic generalised epilepsy at 1q43 and for 
absence epilepsy at 2q22.3.16 
In a large multicentre collaboration, we undertook a 
meta-analysis to detect variants that could increase risk 
for common epilepsies. In view of clinical evidence that 
some genetic factors might increase risk for epilepsy 
broadly and in a syndrome-speciﬁ c manner,17–19 we 
prespeciﬁ ed three analyses as part of the study. Variants 
were sought that aﬀ ected risk for all epilepsies, genetic 
generalised epilepsy (previously known as idiopathic 
generalised epilepsy),2,20 or focal epilepsy.
Methods
Study design and participants
We did a meta-analysis of data from 12 previously 
published or unpublished genetic cohort studies from 
EPICURE,16 EPIGEN,13 Philadelphia (PA, USA), the 
Imperial-Liverpool-Melbourne Collaboration,21 GenEpa,13 
and Hong Kong (China)15 (appendix). We identiﬁ ed these 
studies from the scientiﬁ c literature (through searches 
of PubMed in December, 2011, with the terms “epilepsy”, 
“seizures”, and “association studies”), through publicity 
via Chapters of the International League Against 
Epilepsy, and during international conferences. All 
participants in these 12 case cohorts (and their associated 
controls) were of European, Asian, or African ancestry 
(table 1, appendix).
The genetic cohort studies used a combination of 
population-based datasets as controls. These control cohorts 
were either screened or unscreened by questionnaire for 
neurological disorders (table 1, appendix).
All study participants provided written informed consent 
for DNA analysis. Local institutional review boards 
reviewed and approved study protocols at each site.
Procedures
We classiﬁ ed seizures and epilepsy syndromes 
according to the International League Against Epilepsy 
terminology.2,20 For all cases, epilepsy specialists assessed 
phenotype at the source centre. Patients with epilepsy 
were assigned to one of three phenotypic categories: 
genetic generalised epilepsy, focal epilepsy, or 
unclassiﬁ ed epilepsy. 
Criteria for genetic generalised epilepsy were tonic-
clonic, absence, or myoclonic seizures with generalised 
spike–wave discharges on EEG and no evidence of an 
acquired cause. In rare instances the criterion for a 
diagnostic EEG was waived when clear clinical evidence 
suggested myoclonic or absence seizures with tonic-clonic 
seizures, and no evidence for an acquired cause. The 
International League Against Epilepsy has adopted the 
term genetic generalised epilepsy for syndromes previously 
known as idiopathic or primary generalised epilepsies, in 
view of strong evidence for a genetic basis from genetic 
epidemiological and twin studies and an absence of 
identiﬁ ed acquired factors.2,20 
In the phenotypic category of focal epilepsy, we 
included patients with a conﬁ rmed diagnosis of focal 
epilepsy, including cases with focal structural brain 
lesions. These cases were predominantly adults, and as 
such, cases of benign epilepsy of childhood with centro-
temporal spikes were not speciﬁ cally included.
Unclassiﬁ ed epilepsy consisted of patients in whom 
there was neither electroclinical evidence for generalised 
epilepsy nor evidence for a focal seizure onset. 
Additionally, cases with evidence for both generalised 
and focal epilepsy were included here.
The phenotyping committee curated patient pheno-
types into a single database. Details relating to individual 
case cohorts are provided in the appendix. Analyses were 
done for three phenotypic groups: genetic generalised 
epilepsy, focal epilepsy, and all epilepsy (consisting of all 
patients with a conﬁ rmed diagnosis of epilepsy, including 
genetic generalised epilepsy, focal epilepsy, and 
unclassiﬁ ed epilepsy). 
Statistical analysis
We used prespeciﬁ ed criteria for quality control to ﬁ lter 
cases and controls from the 12 cohorts (appendix). 
Because contributing sites had used diﬀ erent genotyping 
platforms, we did imputation to infer genotypes for 
common genetic variants that were not directly 
genotyped, allowing us to combine results across sites. 
Each of the ﬁ ve sites imputed their study datasets 
Ethnic origin* All 
epilepsy
(n=8696)
Genetic 
generalised 
epilepsy 
(n=2606)
Focal 
epilepsy
(n=5310)
Population 
controls‡
(n=26 157)
EPIGEN-Dublin Irish 638 ·· 520 2232
EPIGEN-Brussels Belgian 505 48 406 1675
EPIGEN-Duke† African-American and 
European-American
760 102 551 504
EPIGEN-London British and other 1007 93 773 2494
ILM Collaboration European descent 1703 212 1263 2699
GenEpa Finnish 422 ·· 422 1963
EPICURE Northwest European 1440 1440 ·· 2454
Philadelphia_550_AA† African-American 324 81 222 2746
Philadelphia_550_CAU European-American 819 440 378 5736
Philadelphia_Omni_AA§ African-American 106 ·· ·· 97
Philadelphia_Omni_CAU European-American 485 190 288 682
Hong Kong Asian-Han 487 ·· 487 2875
Numbers of cases and controls are after quality control ﬁ ltering. GWAS=genome-wide association study. ILM=Imperial-
Liverpool-Melbourne. *Broad ethnic origin of the cohort. Other indicates people of mixed ethnic origin, as would be 
expected in a cosmopolitan population. European descent refers to white European. †EPIGEN-Duke individuals of African-
American ancestry were merged with participants in the Philadelphia_550_AA cohort. ‡See appendix for further details 
about control cohorts. §Small sample size prohibited epilepsy subtype analysis in this cohort. 
 Table 1: Cases and controls, by index GWAS
See Online for appendix
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according to a standardised protocol. This protocol used 
IMPUTE2 to infer and impute haplotypes, with the 
1000 Genomes Phase I (interim) June, 2011, reference 
panel (appendix).
Investigators at each site did a linear mixed-model 
association analysis for each of their datasets with 
FaSTLMM (version 1.09).22 This analysis uses linear 
regression, including a polygenic term designed to 
account for the contributions of population stratiﬁ cation 
and causal variants aside from the one being tested. 
Although we were assessing a binary trait, we used linear 
regression (rather than logistic regression) because we 
expected eﬀ ect sizes to be small. We did this analysis 
separately for each of the preselected phenotypic categories 
of epilepsy (all epilepsy, genetic generalised epilepsy, and 
focal epilepsy). Sex was included as a covariate.
We did a ﬁ xed-eﬀ ects meta-analysis with METAL (version 
generic-metal-2011-03-25).23 Because almost all epilepsy 
cases were of European descent (table 1), we chose a ﬁ xed-
eﬀ ects model to optimise power. Single nucleotide 
polymorphisms showing signiﬁ cant amounts of hetero-
geneity (p<0·05) were removed before application of the 
ﬁ xed-eﬀ ects analysis. We applied genomic correction to 
the association analysis results for each dataset before 
combining for meta-analysis. These steps were done 
separately for each of the three phenotypic tests. 
We set our genome-wide threshold for statistical 
signiﬁ cance at 1·66 × 10–⁸, representing an empirical 
Bonferroni correction of the 5 × 10–⁸ genome-wide 
signiﬁ cance threshold for three tests. We regarded signals 
with p values between 1·66 × 10–⁸ and 5 × 10–⁷ as suggestive 
evidence of association.
We calculated the proportion of phenotypic variance a 
variant must explain (heritability) for the detection power 
to be at least 80%. We used variance explained on the 
liability scale,24 for which we assumed a point prevalence 
of 0·5% for all epilepsy, 0·2% for genetic generalised 
epilepsy, and 0·3% for focal epilepsy.25 The required 
heritability was 0·07% or greater for all epilepsy, 0·17% or 
greater for genetic generalised epilepsy, and 0·10% or 
greater for focal epilepsy (appendix).
In addition to the main association analysis, we did 
logistic regression for variants in a 1 megabase window 
centred on each variant that showed suggestive evidence of 
association (p<5 × 10–⁷) from any of the three meta-analyses 
(all epilepsy, genetic generalised epilepsy, or focal epilepsy). 
The purpose of this analysis was technical validation and to 
estimate odds ratios (ORs). We analysed the dosage data, 
including sex and the ﬁ rst 20 principal components, with 
PLINK (version 1.07),26 and then combined the results from 
each site again with a ﬁ xed-eﬀ ect meta-analysis.
Conditional analysis was done with FaSTLMM 
(version 2.0) on variants in the same regions as those 
deﬁ ned for the logistic regression. The purpose of the 
conditional analysis was to establish whether any other 
genetic variants in the region were associated with the 
disease phenotype, independent of the strongest signal 
from that region. We conditioned on the most signiﬁ cant 
variants within each of the three regions. Sex was included 
as a covariate in the conditional analysis. We applied 
Bonferroni correction to control for multiple testing in the 
conditional analysis and set the threshold for signiﬁ cance 
at 5 × 10–⁶ (each 1 megabase region contained approximately 
10 000 single nucleotide polymorphisms).
To assess the accuracy of the imputation across regions 
showing signals satisfying genome-wide signiﬁ cance, we 
did genotyping in a subset of patients included in the 
meta-analysis and compared hard genotypes with 
imputation dosage ﬁ les. We selected a subset of 
individuals to represent each of the three broad ethnic 
origins included in our analysis (ie, European ancestry, 
African-American, and Asian). Genotyping was done 
with TaqMan (Life Technologies, Carlsbad, CA, USA) for 
rs28498976, Sanger sequencing for rs6732655, and Kasper 
KASP (LGC Genomics, Hoddesdon, Hertfordshire, UK) 
for rs2947349 (appendix), because diﬀ erences in sequence 
context required speciﬁ c genotyping platforms for each 
single nucleotide polymorphism.
We did enrichment analysis with the interval-based 
enrichment analysis tool as integrated in the package 
INRICH (version 1.0).27 Brieﬂ y, INRICH takes a set of 
independent, nominally associated genomic intervals 
and tests for enrichment of predeﬁ ned gene sets with 
permutation. We analysed variants with p values less 
than 1 × 10–⁵ and deﬁ ned the interval around index single 
nucleotide polymorphisms with an r² threshold of 0·2. 
Gene sets as deﬁ ned by gene ontology pathways were 
tested for enrichment.
Role of the funding source
The funders had no role in the study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The members of the strategy and analysis 
committees of the International League Against Epilepsy 
Consortium on Complex Epilepsies had full access to all 
data in the study. The strategy committee (appendix) of 
the Consortium takes ﬁ nal responsibility for the decision 
to submit for publication.
Results
40 789 participants, comprising 10 064 people with epilepsy 
from 12 cohorts and 30 725 controls, were studied. After 
application of our quality control criteria (appendix), we 
included a total of 34 853 individuals (8696 with epilepsy 
and 26 157 controls) in the meta-analysis for all epilepsies 
(table 1).
Principal component analysis suggested that the 
cohorts clustered in three broad ethnic origins (European, 
Asian, and admixed African-American), as expected 
(appendix). We noted an inﬂ ation factor of 1·031, 
suggesting adequate control for possible cryptic 
stratiﬁ cation (appendix).
In the all-epilepsy analysis, we identiﬁ ed two loci with 
genome-wide signiﬁ cance (p<1·66 × 10–⁸; ﬁ gure 1). The 
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ﬁ rst signal was located at 2q24.3 (ﬁ gure 2). This signal was 
centred on the voltage-gated sodium channel gene SCN1A, 
which is a known gene associated with some monogenic 
epilepsies.7,28,29 The most strongly associated variant in this 
interval was rs6732655 (p=8·71 × 10–¹⁰, OR 0·89, 95% CI 
0·86–0·93; table 2, appendix), located in intron 16 of 
SCN1A. Seventy other variants in this region satisﬁ ed the 
threshold for genome-wide signiﬁ cance. Logistic regres-
sion validated the association with 2q24.3 (appendix). The 
direction of eﬀ ect was consistent across most cohorts, and 
there was no evidence of substantial heterogeneity.
In view of the extent of linkage disequilibrium between 
the variants associated with all epilepsy in the 2q24.3 region 
(ﬁ gure 2), we did logistic regression conditioned on the 
most signiﬁ cant variant identiﬁ ed from the univariate 
analysis (rs6732655). Our results suggested a tentative 
independent signal, coming from rs13406236, in an intronic 
variant in SCN9A (p=1·39 × 10–⁴ on conditioning; appendix). 
We did not identify any further signiﬁ cant signals.
A second signal for the all-epilepsy phenotype was 
located at 4p15.1 and included the 3ȸ end of the 
protocadherin gene, PCDH7 (ﬁ gure 3). The most strongly 
associated variant in this region was rs28498976 
(p=5·44 × 10–⁹, OR 0·90, 95% CI 0·87–0·94; table 2), 
located 2·5 kilobases from the 3ȸ end of PCDH7. Logistic 
regression across PCDH7 supported the association with 
Figure 1: Manhattan plots for meta-analyses of all epilepsy (A), genetic generalised epilepsy (B), and focal epilepsy (C)
The red line shows our threshold of signiﬁ cance set at p=1·66 × 10⁸, and the green line shows the suggestive threshold of p=5 × 10⁷. Y axis is broken in all graphs.
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this locus (appendix). We noted no additional signiﬁ cant 
signals from 4p15.1 on conditioning for rs28498976 
(appendix). The direction of eﬀ ect was consistent across 
all cohorts and we noted no evidence of heterogeneity. 
Although achieving genome-wide signi ﬁ cance only for 
the all-epilepsy phenotype, the PCDH7 signal seemed 
stronger in genetic generalised epilepsy than in focal 
epilepsy (appendix).
PCDH7 encodes a calcium-dependent adhesion 
protein, not previously associated with epilepsy. It is a 
member of the cadherin gene family. The gene is 
expressed in the CNS, speciﬁ cally in thalamocortical 
circuits and the hippocampus,30,31 and expression of 
PCDH7 is controlled by MECP2,32 mutations in which 
cause Rett syndrome. The cytoplasmic domain of the 
PCDH7 protein binds to protein phosphatase 1α 
(PPP1CA), which is enriched in dendritic spines and is 
important in learning and memory,33 and to template 
activation factor 1 (TAF1), which along with PCDH7 is 
involved in neurite extension.34,35
Figure 2: Genomic context of 2q24.3 signal from all-epilepsy analysis
Plot created with LocusZoom (version 1.1). Linkage disequilibrium data taken from the 1000 Genomes Project, HG19, March, 2012.
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rs6732655 2q24.3 166895066 T*, A 0·22 (A) SCN1A Intronic All epilepsy 0·89 (0·86–0·93) 8·71 × 10¹⁰ 4·95 × 10⁷
rs28498976 4p15.1 31151357 A, G* 0·46 (A) PCDH7 Intergenic All epilepsy 0·90 (0·87–0·94) 5·44 × 10⁹ 2·29 × 10⁴
rs111577701 3q26.2 167861408 T, C* 0·09 (T) GOLIM4 Intergenic All epilepsy 1·16 (1·09–1·24) 4·42 × 10⁷ ··
rs535066 4p12 46240287 T, G* 0·40 (G) GABRA2 Intergenic All epilepsy 1·10 (1·05–1·16) 1·71 × 10⁷ ··
rs2947349 2p16.1 58059803 A*, C 0·26 (C) VRK2/FANCL Intergenic GGE 1·23 (1·16–1·31) 9·99 × 10⁹ 1 × 10⁴
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rs1044352 4p15.1 31147874 T*, G 0·50 (T) PCDH7 Synonymous GGE 0·88 (0·82–0·93) 1·87 × 10⁷ ··
rs55670112 5q22.3 114268470 A, C* 0·47 (C) None Intergenic GGE 1·18 (1·1–1·26) 6·34 × 10⁸ ··
rs12987787 2q24.3 166858391 C, T* 0·21 (C) SCN1A Intronic Focal epilepsy 1·12 (1·01–1·14) 1·45 × 10⁷ ··
Base pair position refers to build 37 (hg19). Minor allele frequency is from all poulations from the 1000 Genomes Project. Candidate gene refers to the most plausible candidate gene attributable to the signal. OR 
corresponds to allele 2, computed from logistic regression. Annotation refers to type of SNP. pLMM refers to p value from linear mixed-model meta-analysis. pcond refers to p value when conditioning on this speciﬁ c 
SNP to determine independent signals from same locus. OR=odds ratio. GGE=genetic generalised epilepsy. SNP=single nucleotide polymorphism. *Ancestral or chimpanzee allele.
Table 2: Genome-wide associated loci at p<5·0 × 10–⁷
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Suggestive signals of note (p<5 × 10–⁷) for the all-epilepsy 
phenotype were detected at 3q26.2 (p=4·42 × 10–⁷) and 4p12 
(p=1·71 × 10–⁷; table 2). The 3q26.2 region contained the 5ȸ 
end of GOLIM4 (appendix). This gene encodes Golgi 
internal membrane protein 4, which is degraded when 
manganese increases above normal concentrations, 
suggesting a role for this protein in manganese 
homoeostasis.36 Almost all brain manganese is bound to 
glutamine synthetase, an enzyme playing a key part in 
production or degradation of the neurotransmitters 
glutamate, glutamine, and GABA. Decreased brain 
glutamine synthetase and manganese concentrations have 
been reported in epilepsy.37,38 The 4p12 region contained 
the 3ȸ end of the GABA receptor, α2-subunit gene 
(GABRA2). Mutations in other GABA receptors have been 
reported to cause epilepsy.39 
After quality control, we included 21 596 individuals 
(2606 cases and 18 990 controls) across eight cohorts in 
the meta-analysis of genetic generalised epilepsy (table 1), 
a subset of those included in the all-epilepsy analysis. 
Results from the genetic generalised epilepsy meta-
analysis suggested an inﬂ ation factor of 1·05 (appendix). 
A single signal achieved the threshold of genome-wide 
signiﬁ cance (ﬁ gure 1). Located at 2p16.1, the interval 
contained genes encoding vaccinia-related kinase 2 
(VRK2) and Fanconi anaemia, complementation group L 
(FANCL; ﬁ gure 4). The most strongly associated variant 
in this region was the intergenic variant rs2947349 
(p=9·99 × 10–⁹, OR 1·23, 95% CI 1·16–1·31; table 2). 
Logistic regression analysis supported the association 
with 2p16.1 (appendix). We noted no additional signiﬁ cant 
signals from 2p16.1 on conditioning for rs2947349 
(appendix). The direction of eﬀ ect was consistent across 
all cohorts, and the association seemed to be speciﬁ c to 
genetic generalised epilepsy (appendix).
VRK2 is a serine-threonine protein kinase involved in 
signal transduction and apoptosis.40,41 Variation in VRK2 
has previously been suggested as a risk factor for 
epilepsy16 and schizophrenia.42–44 Indeed, the schizophrenia-
associated risk variant (rs2312147)43 shows also a strong 
signal for genetic generalised epilepsy (p=2·3 × 10–⁶, 
OR 1·22, 95% CI 1·14–1·30) and is in high linkage dis-
equilibrium with the strongest variant for genetic 
generalised epilepsy (r²=0·82), although the direction of 
the eﬀ ect is opposite (ie, the protective variant for epilepsy 
raises risk for schizophrenia). The EPICURE cohort, in 
which 2p16.1 was originally proposed as a risk factor for 
genetic generalised epilepsy, was included in our meta-
analysis. After exclusion of the EPICURE cohort, the top 
single nucleotide polymorphism from their study 
(rs13026414)16 remained nominally signiﬁ cant at p=7 × 10–³ 
here. These results provide further support to the 
Figure 3: Genomic context of 4p15.1 signal from all-epilepsy analysis
Plot created with LocusZoom (version 1.1). Linkage disequilibrium data taken from the 1000 Genomes Project, HG19, March 2012.
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suggestion that VRK2 is a risk locus for both epilepsy and 
schizophrenia. The other gene in the region, FANCL, codes 
for a RING-type E3 ubiquitin ligase of the Fanconi anaemia 
pathway. FANCL mono-ubiquitinates FANCD2 and 
FANCI, proteins involved in DNA repair and homologous 
recombination.45 FANCL has not been previously 
implicated in epilepsy or any seizure-related phenotype.
We detected suggestive evidence for association with 
genetic generalised epilepsy at 4p15.1 (p=1·87 × 10–⁷), 5q22.3 
(p=6·34 × 10–⁸), and 11q22.2 (p=2·37 × 10–⁸; table 2). The 
4p15.1 PCDH7 signal was the same as that with genome-
wide signiﬁ cance for the all-epilepsy phenotype (ﬁ gure 3, 
appendix). The 5q22.3 signal was intergenic (appendix). 
The 11q22.2 signal contained the 5ȸ end of the matrix 
metallopeptidase gene MMP8 (appendix). The direction of 
eﬀ ect was consistent across all cohorts and seemed speciﬁ c 
to genetic generalised epilepsy (appendix). With a p value of 
2·37 × 10–⁸, the 11q22.2 signal reached the conventional 
threshold for genome-wide signiﬁ cance (p<5 × 10–⁸), but not 
our more stringent value (p<1·66 × 10–⁸). Matrix 
metallopeptidases are zinc-dependent endopeptidases 
involved in the breakdown of the extracellular matrix in 
physiological processes and in blood–brain inﬂ ammation.46 
Increased expression of MMPs has been recorded in various 
neurological disease states,47 and epileptogenesis is 
decreased in MMP9 knockout mice but increased in 
transgenic rats overexpressing MMP9.48
After quality control, we included 28 916 individuals 
(5310 cases and 23 606 controls) from ten cohorts in our 
meta-analysis of focal epilepsy. No signal achieved 
genome-wide signiﬁ cance. Results from the focal meta-
analysis suggested an inﬂ ation factor of 1·014 (appendix). 
We observed one notable subthreshold signal (rs12987787, 
p=1·45 × 10–⁷) from 2q24.3, the region containing SCN1A 
(appendix).
Targeted genotyping of the three GWAS-signiﬁ cant 
signals supported the accuracy of imputation, with a 
minimum correlation of 0·98 noted between experi-
mentally determined and imputed genotypes (appendix).
Assessment of enrichment of gene ontology terms for 
regions containing variants with nominally signiﬁ cant 
p values (p<1 × 10–⁵) for each of the three phenotypes 
showed enrichment in several signalling pathways 
(appendix). Although none of these variants remained 
signiﬁ cant after correction for multiple testing, our 
results suggest pathways with biological plausibility. 
Finally, we investigated whether any of the four 
susceptibility loci at nominal genome-wide signiﬁ cance 
(p<5 × 10–⁸) were associated with outcome of newly 
treated epilepsy with use of data from Speed and 
colleagues.21 We used both the index single nucleotide 
polymorphism (table 2) and single nucleotide polymor-
phisms within a 20 kilobase window around each of the 
ﬁ ve genes (SCN1A, PCDH7, VRK2/FANCL, and MMP8; 
Figure 4: Genomic context of 2p16.1 signal from analysis of genetic generalised epilepsy
Plot created with LocusZoom (version 1.1). Linkage disequilibrium data taken from the 1000 Genomes Project, HG19, March 2012.
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appendix). The minimum p value of association with 
outcome of newly treated epilepsy for any susceptibility 
locus was 8·14 × 10–⁴ (MMP8). We noted no evidence for 
an association between SCN1A (the gene that codes for 
the target of sodium-channel-blocking class antiepileptic 
drugs) and epilepsy outcome.
Discussion
In this genome-wide association meta-analysis of 
epilepsy and its most common subtypes, we identiﬁ ed 
three loci with genome-wide signiﬁ cance, and our 
ﬁ ndings suggest that some loci might be speciﬁ cally 
associated with an epilepsy type.
In the whole cohort consisting of all epilepsy, the 
region of the sodium channel subunit gene SCN1A was 
clearly associated with the disease. This gene is a well-
established cause of genetic epilepsy with febrile seizures 
plus (GEFS+),28,29 a generally mild, familial form of 
epilepsy, and with Dravet syndrome, a severe epileptic 
encephalopathy usually arising from de-novo mutations.7 
SCN1A was associated with mesial temporal lobe 
epilepsy and hippocampal sclerosis with febrile seizures 
in a recent GWAS14 and in a meta-analysis of SCN1A 
rs3812718.49 SCN1A mutations have also been reported in 
a range of paroxysmal neurological disorders including 
familial hemiplegic migraine50 and, more rarely, in some 
focal epilepsies.51 Whether this robust association with all 
epilepsy is a true common variant association or a 
synthetic association due to tagged rare variants in cases 
with GEFS+ is therefore not clear. Although the cohorts 
might have included individuals from monogenic GEFS+ 
families with SCN1A mutations of large eﬀ ect, review of 
the phenotyping data suggested that inclusion of more 
than a few such cases was unlikely; moreover, SCN1A 
variants have been reported only in about 10% of large 
GEFS+ families.52 
Our all-epilepsy analysis identiﬁ ed a second locus 
(4p15.1) that satisﬁ ed our threshold for genome-wide 
signiﬁ cance. This locus is newly associated with epilepsy 
and implicates the gene PCDH7. This protocadherin 
gene is a plausible candidate for common forms of 
epilepsy, as mutations in another protocadherin gene, 
PCDH19, cause epilepsy and mental retardation in 
female patients.53 
For the speciﬁ c category of genetic generalised epilepsy, 
we noted the association at 2p16.1 that was previously 
reported in the EPICURE cohort;16 this cohort provided 
about half of our sample for the meta-analysis of this 
subtype (table 1). The association maintained nominal 
signiﬁ cance after removal of EPICURE cases for this 
locus, where the genes VRK2 and FANCL are within 
close proximity. With our additional samples, we did not 
note signiﬁ cance for the 17q21 locus reported by 
EPICURE investigators for genetic generalised epilepsy 
(appendix).
For the subcategory of focal epilepsy, we did not note 
any locus with genome-wide signiﬁ cance, consistent 
with negative ﬁ ndings from the EPIGEN study of focal 
epilepsy (samples from which were included in our 
analysis).13 However, a signal at 2q24.3 (containing 
SCN1A) in focal epilepsy approached but did not achieve 
signiﬁ cance (appendix). This signal in focal epilepsy was 
in high linkage disequilibrium with that noted for all 
epilepsy (r²=0·85). Importantly, the 2q24.3 signal for 
focal epilepsy that we recorded diﬀ ered to that reported 
in a recent study of the narrow focal epilepsy phenotype 
of mesial temporal lobe epilepsy and hippocampal 
sclerosis with febrile seizures.14 rs7587026 (the previously 
reported variant) was not signiﬁ cant in our analysis of a 
broader focal epilepsy phenotype consisting of all focal 
epilepsies (p=0·01; appendix). We also did not note the 
association at 1q32.1 (implicating CAMSAP1L1) that was 
previously reported in the Hong Kong cohort,15 which 
was included in our sample (appendix). Most patients in 
this cohort had focal epilepsy due to known lesions. 
Consistent with experience of GWAS in other 
neuropsychiatric disorders, and common disorders in 
general, this study reinforces the value of large sample 
sizes. In the epilepsies, electroclinical and imaging 
data allow the identiﬁ cation of clinical syndromes that 
share common clinical features. Our study ﬁ ndings 
suggest that an experimental design that includes 
fractionation of samples into clinical subtypes can 
reveal syndrome-speciﬁ c risk alleles, but the identi-
ﬁ cation of these alleles will be assisted by the collection 
and genotyping of larger sample sizes. Although this 
lumping versus splitting debate in genetic analyses is 
not unique to the epilepsies, there has been long-
standing controversy about it in clinical epileptology,54 
which genetics will help to inform.
Limitations of our study include sample size; although 
ours is large, even larger samples have yielded more 
ﬁ ndings in other disorders.55–57 Larger samples would 
enable further analysis of epilepsy subtypes, and the 
International League Against Epilepsy Consortium on 
Complex Epilepsies now provides a useful vehicle for 
future eﬀ orts. Second, our meta-analysis relied on 
genotypes generated separately on various platforms, an 
issue common to most meta-analyses. Third, extension 
of the phenotyping data to include treatment outcome 
would be ideal, but in a cross-sectional cohort this 
approach has methodological diﬃ  culties. Finally, we did 
not have an independent replication sample. However, 
stringent criteria for statistical signiﬁ cance were set 
a priori, and for loci achieving our threshold of genome-
wide signiﬁ cance the direction of eﬀ ects were largely 
consistent across the cohorts, and extended over multiple 
variants in high linkage disequilibrium.
Taken together, these data show that, with suﬃ  cient 
sample size, susceptibility loci for common epilepsies 
can be identiﬁ ed through the analysis of common 
variation. The role of rare variants of large eﬀ ect is also 
well established, particularly in rarer Mendelian 
epilepsies.3–7 The role of rare variants in the common 
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epilepsies is at present under exploration by deep-
sequencing approaches.11,58,59 A dual approach of 
identiﬁ cation of both rare and common variation will 
result in improved understanding of the genetic 
architecture for the overall population of people with 
epilepsy, necessary for precision medicine. Although our 
ﬁ ndings will not be of immediate clinical usefulness, 
they are an important ﬁ rst step to understand the genetic 
architecture of the epilepsies, which could lead to 
clinically relevant markers of prognosis and outcome.
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